Psoriasis patients monitored for two years on newer biologic drug

NCT ID NCT07582783

Recruiting now Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study watches 200 adults with moderate-to-severe plaque psoriasis who have never taken a biologic before. They are starting treatment with guselkumab, and researchers will track how many continue the drug for two years. The goal is to see how well people stick with this treatment over time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PSORIASIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

psoriasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PSORIASIS

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Derma Lux SRL
RECRUITING

Iași, 700126, Romania
Dr Tirziu Dermato Chirurgie SRL
RECRUITING

Timișoara, 300188, Romania
Mihaila G. Georgiana - Cabinet Medical Individual Dermatovenerologie
RECRUITING

Bârlad, 731139, Romania
Qualimed SRL
RECRUITING

Brasov, 500073, Romania
Spitalul Clinic Colentina
RECRUITING

Bucharest, 020125, Romania
Spitalul Clinic Colentina 1
RECRUITING

Bucharest, 020125, Romania